Related references
Note: Only part of the references are listed.Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis
Yuan Cheng et al.
DIGESTIVE DISEASES AND SCIENCES (2021)
Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux
Junichi Akiyama et al.
DIGESTION (2020)
Comparison of Antioxidant Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole
Mohammed N. Abed et al.
PHARMACOLOGY (2020)
Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review
Hirota Miyazaki et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
Yoshikazu Kinoshita et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2019)
Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan
Kouichi Sakurai et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Modern diagnosis of GERD: the Lyon Consensus
C. Prakash Gyawali et al.
GUT (2018)
The Changing Epidemiology of Gastroesophageal Reflux Disease: Are Patients Getting Younger?
Takahisa Yamasaki et al.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2018)
Randomised clinical trial: efficacy and safety of vonoprazan vs. lansoprazole in patients with gastric or duodenal ulcers - results from two phase 3, non-inferiority randomised controlled trials
H. Miwa et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Gastroesophageal Reflux Disease
Rick Kellerman et al.
PRIMARY CARE (2017)
Reflux Hypersensitivity: A New Functional Esophageal Disorder
Takahisa Yamasaki et al.
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2017)
Management of refractory typical GERD symptoms
Emidio Scarpellini et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2016)
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
K. Ashida et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Acid-inhibitory effects of vonoprazan 20mg compared with esomeprazole 20mg or rabeprazole 10mg in healthy adult male subjects - a randomised open-label cross-over study
Y. Sakurai et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
Yuuichi Sakurai et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2015)
Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review
Hashem B. El-Serag et al.
GUT (2014)
Unmet treatment needs of gastroesophageal reflux disease in Asia: Gastroesophageal reflux disease in Asia Pacific Survey
Khean Lee Goh et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014)
Step-by-step management of refractory gastresophageal reflux disease
T. Hershcovici et al.
DISEASES OF THE ESOPHAGUS (2013)
Validation of the Reflux Symptom Questionnaire Electronic Diary in Partial Responders to Proton Pump Inhibitor Therapy
Nimish Vakil et al.
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY (2012)
An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers
G. Morelli et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Epidemiology of Gastroesophageal Reflux Disease in Asia: A Systematic Review
Hye-Kyung Jung
JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY (2011)
Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of Therapy
Christina Reimer et al.
GASTROENTEROLOGY (2009)
The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor
R. Jones et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Mechanisms of heartburn
Daphne Ang et al.
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY (2008)
Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: Evidence of an unmet need?
Yuhong Yuan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Effect of esomeprazole on nighttime heartburn and sleep quality in patients with GERD: A randomized, placebo-controlled trial
DA Johnson et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next?
R Fass et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment
C Calabrese et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life
C Farup et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study
R Fass et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
